全文获取类型
收费全文 | 9998003篇 |
免费 | 653487篇 |
国内免费 | 157629篇 |
专业分类
耳鼻咽喉 | 130689篇 |
儿科学 | 281388篇 |
妇产科学 | 231898篇 |
基础医学 | 1239787篇 |
口腔科学 | 264106篇 |
临床医学 | 1010917篇 |
内科学 | 1663574篇 |
皮肤病学 | 203631篇 |
神经病学 | 722901篇 |
特种医学 | 376505篇 |
外国民族医学 | 1748篇 |
外科学 | 1324180篇 |
综合类 | 714162篇 |
现状与发展 | 514篇 |
一般理论 | 3732篇 |
预防医学 | 794100篇 |
眼科学 | 229083篇 |
药学 | 863271篇 |
2758篇 | |
中国医学 | 213312篇 |
肿瘤学 | 536863篇 |
出版年
2022年 | 80801篇 |
2021年 | 179133篇 |
2020年 | 141947篇 |
2019年 | 145502篇 |
2018年 | 177765篇 |
2017年 | 158523篇 |
2016年 | 152909篇 |
2015年 | 191853篇 |
2014年 | 279233篇 |
2013年 | 370340篇 |
2012年 | 523047篇 |
2011年 | 568042篇 |
2010年 | 385363篇 |
2009年 | 346165篇 |
2008年 | 483424篇 |
2007年 | 503930篇 |
2006年 | 481869篇 |
2005年 | 445673篇 |
2004年 | 389255篇 |
2003年 | 360413篇 |
2002年 | 331725篇 |
2001年 | 311854篇 |
2000年 | 310094篇 |
1999年 | 264254篇 |
1998年 | 103863篇 |
1997年 | 91078篇 |
1996年 | 84869篇 |
1995年 | 83703篇 |
1994年 | 75979篇 |
1993年 | 65172篇 |
1992年 | 183200篇 |
1991年 | 177553篇 |
1990年 | 172029篇 |
1989年 | 166978篇 |
1988年 | 154253篇 |
1987年 | 150167篇 |
1986年 | 143014篇 |
1985年 | 136262篇 |
1984年 | 103573篇 |
1983年 | 88746篇 |
1982年 | 56344篇 |
1979年 | 92787篇 |
1978年 | 66534篇 |
1977年 | 57227篇 |
1976年 | 53106篇 |
1975年 | 58193篇 |
1974年 | 67258篇 |
1973年 | 64180篇 |
1972年 | 59378篇 |
1971年 | 54998篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
91.
Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways 下载免费PDF全文
Ahmed A Abd-Rabou Hanaa H Ahmed Safaa H MohamedSoheir E KotobMohamed S Kishta 《Asian Pacific journal of cancer prevention》2022,23(12):4261-4273
Objective: Hepatocellular carcinoma (HCC) microenvironment has been recognized as a key contributor for cancer progression, metastasis, and drug resistance. The crosstalk between tumor cells, the vascular endothelial growth factor (VEGF), and the chemokine (C-C motif) ligand 2 (CCL2) signaling networks mediates immunoinhibitory impact and facilitates tumor angiogenesis. The current investigation aimed at exploring the potent anti-cancer activity of the newly designed nano-based anti-cancer therapy comprising anti-VEGF drug, avastin (AV), and CCR2 antagonist (CR) to counteract HCC and tracking its mode of action in vivo. Methods: The prepared AV, CR, and AVCR nanoprototypes were characterized by nanoscale characterization techniques in our previous work. Here, they are applied for unearthing their anti-cancer properties / mechanisms in hepatic cancer-induced rats via analyzing protein levels and genetic expression of the elements incorporated in the angiogenesis, apoptosis, and metastasis signalling pathways. Results: The present results revealed a significant down-regulation in the angiogenesis, survival and metastasis indices along with up-regulation in the pro-apoptotic mediators upon treatment of hepatic cancer-bearing rats with the novel synthesized nanomaterials when compared with the untreated counterparts. We showed across HCC model that anti-VEGF in combination with CCR2 antagonism therapy leads to sensitization and enhanced tumor response over anti-VEGF or CCR2 antagonism monotherapy, particularly in its nanoscale formulation. Conclusion: The present approach provides new mechanistic insights into the powerful anti-hepatic cancer advantage of the novel nanoprototypes which is correlated with modulating critical signal transduction pathways implicated in tumor microenviroment such as angiogenesis, apoptosis and metastasis. This research work presents a substantial foundation for future studies focused on prohibiting cancer progression and recovery by targeting tumor microenviroment. 相似文献
92.
Hori Hiroki Ohta Asuka Matsui Honami Yano Kanako Morita-Tominaka Miyuki Linn Zayar Masumoto Daisuke Okumura Yosuke Okamura Satoshi Kurihara Kosuke Hayakawa Akira Rikiishi Takeshi Kobayashi Kyoko 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(1):245-252
International Journal of Clinical Oncology - The practice of cancer diagnosis disclosure to children has been changed with the times. The regulations of clinical trials in the 2000s might change... 相似文献
93.
Anna Ugalde BA PhD Victoria White BA MA PhD Nicole M. Rankin BA MSc PhD Christine Paul BA PhD Catherine Segan BA PhD Sanchia Aranda RN BAppSci MN PhD Anna Wong Shee BSc BAppSc PhD Alison M. Hutchinson RN BApp Sci MBioth PhD Patricia M. Livingston BA PhD 《CA: a cancer journal for clinicians》2022,72(3):266-286
Smoking cessation reduces the risk of death, improves recovery, and reduces the risk of hospital readmission. Evidence and policy support hospital admission as an ideal time to deliver smoking-cessation interventions. However, this is not well implemented in practice. In this systematic review, the authors summarize the literature on smoking-cessation implementation strategies and evaluate their success to guide the implementation of best-practice smoking interventions into hospital settings. The CINAHL Complete, Embase, MEDLINE Complete, and PsycInfo databases were searched using terms associated with the following topics: smoking cessation, hospitals, and implementation. In total, 14,287 original records were identified and screened, resulting in 63 eligible articles from 56 studies. Data were extracted on the study characteristics, implementation strategies, and implementation outcomes. Implementation outcomes were guided by Proctor and colleagues' framework and included acceptability, adoption, appropriateness, cost, feasibility, fidelity, penetration, and sustainability. The findings demonstrate that studies predominantly focused on the training of staff to achieve implementation. Brief implementation approaches using a small number of implementation strategies were less successful and poorly sustained compared with well resourced and multicomponent approaches. Although brief implementation approaches may be viewed as advantageous because they are less resource-intensive, their capacity to change practice in a sustained way lacks evidence. Attempts to change clinician behavior or introduce new models of care are challenging in a short time frame, and implementation efforts should be designed for long-term success. There is a need to embrace strategic, well planned implementation approaches to embed smoking-cessation interventions into hospitals and to reap and sustain the benefits for people who smoke. 相似文献
94.
95.
目的探讨多元化联合教学模式在超声引导下疼痛介入治疗教学中的应用效果。方法选择2018年1月至2020年12月在北京大学第三医院疼痛科进修的30名医师作为研究对象,将其分为对照组与观察组;对照组采用常规教学模式;观察组采用多元化联合教学模式,比较两组医师技能考核成绩、教学质量评分和满意度评分。结果观察组医师技能考核成绩优良率为93.3%,高于对照组的73.3%(P<0.05);观察组医师对基础理论知识掌握、临床思维能力的提高、学习兴趣的激发、疾病诊治能力的提高4个方面的评分均高于对照组(P<0.01)。结论多元化联合教学模式可促进超声引导下疼痛介入治疗技能的提高,有利于提高学员的综合临床能力。 相似文献
96.
Lakshmi Shree Viswanath Madhan Sugumar Sreeram Chandra Murthy Peela Kamini Walia Sujatha Sistla 《Indian journal of medical microbiology》2022,40(2):285-288
PurposeEmergence of vancomycin variable enterococci (VVE) poses a challenge to empiric vancomycin therapy. Vancomycin-variable enterococci (VVE) are vanA-positive, yet phenotypically vancomycin-susceptible enterococci that can switch to a vancomycin-resistant phenotype when exposed to vancomycin. The aim of the present study was to determine the prevalence of VVE in India.MethodsIsolates of phenotypically vancomycin susceptible Enterococcus faecium from 20 tertiary care hospitals across India were collected and tested for the presence of vanA, vanR, vanS, vanB and vanC genes by conventional PCR using previously published primers. Isolates positive for vanA gene were considered as VVE.ResultsThe prevalence of VVE was 1.5% (5/340). Only one VVE isolate was positive for vanR and vanS, and all the isolates were negative for vanB and vanC.ConclusionsAlthough the prevalence is low, our finding emphasizes the importance of routinely screening for van genes in enterococci that are phenotypically susceptible. Silenced vanA able to escape detection and revert to resistance during vancomycin therapy represents a new challenge in clinical settings. 相似文献
97.
Clinical & Experimental Metastasis - 相似文献
98.
Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic nephroma, were among the first solid tumours shown to harbour recurrent tyrosine kinase fusions, with the canonical ETV6::NTRK3 fusion identified more than 20 years ago. Although targeted testing has long been used in diagnosis, the advent of more robust sequencing techniques has driven the discovery of kinase alterations in an array of mesenchymal tumours. As our ability to identify these genetic alterations has improved, as has our recognition and understanding of the tumours that harbour these alterations. Specifically, this study will focus upon mesenchymal tumours harbouring NTRK or other kinase alterations, including tumours with an infantile fibrosarcoma-like appearance, spindle cell tumours resembling lipofibromatosis or peripheral nerve sheath tumours and those occurring in adults with a fibrosarcoma-like appearance. As publications describing the histology of these tumours increase so, too, do the variety kinase alterations reported, now including NTRK1/2/3, RET, MET, RAF1, BRAF, ALK, EGFR and ABL1 fusions or alterations. To date, these tumours appear locally aggressive and rarely metastatic, without a clear link between traditional features used in histological grading (e.g. mitotic activity, necrosis) and outcome. However, most of these tumours are amenable to new targeted therapies, making their recognition of both diagnostic and therapeutic import. The goal of this study is to review the clinicopathological features of tumours with NTRK and other tyrosine kinase alterations, discuss the most common differential diagnoses and provide recommendations for molecular confirmation with associated treatment implications. 相似文献
99.
Lykov A. P. Uvarov I. P. Gevorgiz R. G. Zheleznova S. N. 《Bulletin of experimental biology and medicine》2022,172(3):301-304
Bulletin of Experimental Biology and Medicine - We studied the effect of microalgae of various systematic groups added to the ration on the biochemical parameters of blood serum and liver and... 相似文献
100.